Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970348 | 0.85 | PDK2 (0.36) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL21025722 | 0.80 | ALDH1A1 (0.38) | CA14HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL20971448 | 0.79 | TSHR (0.37) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL12162750 | 0.79 | NR1I2 (0.37) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL20365461 | 0.77 | NR1I2 (0.36) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL30244616 | 0.77 | MEN1 (0.39) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL30244620 | 0.77 | MEN1 (0.39) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL13272548 | 0.77 | L3MBTL1 (0.33) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL30325321 | 0.77 | MEN1 (0.39) | L3MBTL1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL30324915 | 0.77 | MEN1 (0.39) | L3MBTL1CA14HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | L3MBTL1 3134/4885CA14 909/4885HDAC6 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.